In Vivo Evaluation of a Gastro-Resistant HPMC-Based "Next Generation Enteric" Capsule.
MRI
caffeine
enteric hard capsule
hydroxypropyl methyl cellulose
hydroxypropyl methyl cellulose acetate succinate
saliva
stable isotope
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Sep 2022
21 Sep 2022
Historique:
received:
20
07
2022
revised:
20
08
2022
accepted:
19
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Many orally dosed APIs are bioavailable only when formulated as an enteric dosage form to protect them from the harsh environment of the stomach. However, an enteric formulation is often accompanied with a higher development effort in the first place and the potential degradation of fragile APIs during the coating process. Ready-to-use enteric hard capsules would be an easily available alternative to test and develop APIs in enteric formulations, while decreasing the time and cost of process development. In this regard, Lonza Capsugel
Identifiants
pubmed: 36297435
pii: pharmaceutics14101999
doi: 10.3390/pharmaceutics14101999
pmc: PMC9609816
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Lonza Capsules & Health Ingredients, Colmar, France
ID : n.a.
Références
Mol Pharm. 2019 Apr 1;16(4):1782-1786
pubmed: 30821987
Mol Pharm. 2015 Mar 2;12(3):966-73
pubmed: 25612507
Pharmaceutics. 2020 Feb 03;12(2):
pubmed: 32028731
J Smooth Muscle Res. 2013;49:99-111
pubmed: 24662475
Eur J Pharm Sci. 2019 May 15;133:190-204
pubmed: 30946964
Adv Drug Deliv Rev. 2021 Apr;171:289-331
pubmed: 33610694
Eur J Clin Pharmacol. 1981;21(1):45-52
pubmed: 7333346
Pharmaceutics. 2019 Dec 07;11(12):
pubmed: 31817867
Eur J Pharm Biopharm. 2016 Nov;108:214-219
pubmed: 27639346
Pharmaceutics. 2022 Jan 24;14(2):
pubmed: 35214003
Pharmaceutics. 2021 Nov 25;13(12):
pubmed: 34959284
Pharm Res. 1991 Jan;8(1):97-100
pubmed: 2014217